Cassava up; co expects late-stage trial data for Alzheimer's drug in December
22/07/2024 13:30
** Shares of drug developer Cassava Sciences SAVA.O rise
~4.2% to $10.50 premarket
** Co says it is expecting data from the first late-stage
trial of its Alzheimer's drug simufilam in December
** Adds, second late-stage trial evaluating the drug will
conclude by June 2025
** Up to last close, stock down 55.2% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))